ArticleClinical and translational science2026

Optimal Dosage Justification for Datopotamab Deruxtecan in HR-Positive/HER2-Negative Breast Cancer Through Model-Informed Drug Development Approaches.

Zoey Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.